EP0813414A4 - Kombination von bisphosphonaten und die wachstumshormonsekretion fördernden stoffen - Google Patents

Kombination von bisphosphonaten und die wachstumshormonsekretion fördernden stoffen

Info

Publication number
EP0813414A4
EP0813414A4 EP94931923A EP94931923A EP0813414A4 EP 0813414 A4 EP0813414 A4 EP 0813414A4 EP 94931923 A EP94931923 A EP 94931923A EP 94931923 A EP94931923 A EP 94931923A EP 0813414 A4 EP0813414 A4 EP 0813414A4
Authority
EP
European Patent Office
Prior art keywords
bisphosphonates
combination
growth hormone
hormone secretagogues
secretagogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94931923A
Other languages
English (en)
French (fr)
Other versions
EP0813414A1 (de
Inventor
Barry J Gertz
Gideon A Rodan
Roy G Smith
Matthew J Wyvratt
Arthur A Patchett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0813414A1 publication Critical patent/EP0813414A1/de
Publication of EP0813414A4 publication Critical patent/EP0813414A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP94931923A 1993-10-19 1994-10-18 Kombination von bisphosphonaten und die wachstumshormonsekretion fördernden stoffen Withdrawn EP0813414A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13929693A 1993-10-19 1993-10-19
US139296 1993-10-19
US25909194A 1994-06-13 1994-06-13
US259091 1994-06-13
PCT/US1994/011912 WO1995011029A1 (en) 1993-10-19 1994-10-18 Combination of bisphosphonates and growth hormone secretagogues

Publications (2)

Publication Number Publication Date
EP0813414A1 EP0813414A1 (de) 1997-12-29
EP0813414A4 true EP0813414A4 (de) 1999-07-21

Family

ID=26837073

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94931923A Withdrawn EP0813414A4 (de) 1993-10-19 1994-10-18 Kombination von bisphosphonaten und die wachstumshormonsekretion fördernden stoffen

Country Status (16)

Country Link
EP (1) EP0813414A4 (de)
JP (1) JPH09504525A (de)
KR (1) KR960705575A (de)
CN (1) CN1136278A (de)
AU (1) AU8083694A (de)
BG (1) BG100517A (de)
BR (1) BR9407869A (de)
CA (1) CA2173333A1 (de)
CZ (1) CZ109196A3 (de)
FI (1) FI961681A (de)
HU (1) HUT75224A (de)
LV (1) LV11432B (de)
NO (1) NO961536L (de)
PL (1) PL314003A1 (de)
SK (1) SK49796A3 (de)
WO (1) WO1995011029A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
CA2220055C (en) * 1995-05-08 2001-04-24 Pfizer Inc. Dipeptides which promote release of growth hormone
JPH11513989A (ja) * 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進薬の湿式造粒製剤
WO1997022004A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
HUP9904049A3 (en) * 1996-05-31 2000-07-28 Novo Nordisk As Growth hormone component and bone anti-resorptive agent in cyclic(coherence)treatment of osteoporosis
WO1998018815A1 (en) * 1996-10-25 1998-05-07 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
WO2000002919A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
WO2000009538A2 (en) 1998-08-10 2000-02-24 Merck & Co., Inc. Canine growth hormone secretagogue receptor
EP1112071A4 (de) * 1998-08-18 2003-03-19 Lilly Co Eli Substanzen zur förderung der sekretion der wachstumshormone
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
WO2000074685A1 (fr) * 1999-06-02 2000-12-14 Sumitomo Pharmaceuticals Co., Ltd. Preparations orales d'etidronate disodique
EP1159964B1 (de) 2000-05-31 2009-10-28 Pfizer Products Inc. Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
US6548042B2 (en) 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
MXPA03006565A (es) 2001-01-23 2005-07-29 Gador Sa Composicion comprendiendo bisfosfonatos para la prevencion y/o tratamiento de enfermedades metabolicas de huesos, proceso para preparar tal composicion y el uso de la misma.
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
WO2003087069A2 (en) 2002-04-09 2003-10-23 Eli Lilly And Company Dipeptidic growth hormone secretagogues
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
SI2266584T1 (sl) * 2003-05-07 2012-12-31 Osteologix A/S, Symbion Sestavek s stroncijem in vitaminom D za profilakso in/ali zdravljenje patologij hrustanca in/ali kosti
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
EP2374455A3 (de) 2004-08-19 2012-03-28 Vertex Pharmaceuticals Incorporated Modulatoren von muskarinischen Rezeptoren
RU2007124373A (ru) 2004-11-29 2009-01-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецептеров
US7858635B2 (en) 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
EP1988892A2 (de) 2006-02-22 2008-11-12 Vertex Pharmaceuticals Incorporated Modulatoren muskarinischer rezeptoren
RU2008137583A (ru) 2006-02-22 2010-03-27 Вертекс Фармасьютикалз Инкорпорейшн (Us) Спиропиперидины в качестве модуляторов мускариновых рецепторов
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
AU2007269863A1 (en) 2006-06-29 2008-01-10 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2660903A1 (en) 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CN101573121A (zh) 2006-08-18 2009-11-04 弗特克斯药品有限公司 毒蕈碱受体调节剂
EP2118080B1 (de) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Makrocyclische ghrelin-rezeptormodulatoren und verwendungsverfahren dafür
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
WO2009045519A1 (en) 2007-10-03 2009-04-09 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
BR112020024292A2 (pt) 2018-06-06 2021-03-02 Massachusetts Institute Of Technology rna circular para translação em células eucarióticas
AU2020280105A1 (en) 2019-05-22 2022-01-20 Massachusetts Institute Of Technology Circular RNA compositions and methods
CA3160739A1 (en) 2019-12-04 2021-06-10 Brian Goodman Circular rna compositions and methods
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3514584A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
DE3514583A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
WO1994018169A1 (en) * 1993-02-04 1994-08-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
WO1995003289A1 (en) * 1993-07-26 1995-02-02 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
WO1995009633A1 (en) * 1993-10-04 1995-04-13 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO115804B1 (ro) * 1992-12-11 2000-06-30 Merck & Co Inc Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3514584A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
DE3514583A1 (de) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
WO1994018169A1 (en) * 1993-02-04 1994-08-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
WO1995003289A1 (en) * 1993-07-26 1995-02-02 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
WO1995009633A1 (en) * 1993-10-04 1995-04-13 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO9511029A1 *
TURNER CH: "Toward a Cure for Osteoporosis: Reversal of Excessive Bone Fragility", OSTEOPOROSIS INT, vol. 2, no. 1, 1991, pages 12 - 19, XP002101142 *

Also Published As

Publication number Publication date
BR9407869A (pt) 1996-10-29
LV11432A (lv) 1996-08-20
HUT75224A (en) 1997-04-28
EP0813414A1 (de) 1997-12-29
CA2173333A1 (en) 1995-04-27
HU9601013D0 (en) 1996-06-28
JPH09504525A (ja) 1997-05-06
FI961681A (fi) 1996-06-12
PL314003A1 (en) 1996-08-05
LV11432B (en) 1996-12-20
AU8083694A (en) 1995-05-08
WO1995011029A1 (en) 1995-04-27
CZ109196A3 (en) 1996-10-16
KR960705575A (ko) 1996-11-08
NO961536L (no) 1996-06-18
NO961536D0 (no) 1996-04-18
SK49796A3 (en) 1997-05-07
FI961681A0 (fi) 1996-04-17
BG100517A (en) 1996-11-29
CN1136278A (zh) 1996-11-20

Similar Documents

Publication Publication Date Title
HU9601013D0 (en) Combination of bisphosphonates and growth hormone secretagogues
ZA937082B (en) Benzo-fused lactams promote release of growth hormone
ZA945463B (en) Benzo-fused lactams promote release of growth hormone
ZA945462B (en) Benzo-fused lactams promote release of growth hormone
ZA937594B (en) Benzo-fused lactams promote release of growth hormone
ZA937222B (en) Benzo-fused lactams promote release of growth hormone
ZA932596B (en) Surgical fastener
AU5295793A (en) Woven surgical drain and woven surgical sponge
ZA949899B (en) Heterocyclic-fused lactams promote release of growth hormone
PL309332A1 (en) Spiropiperidines and their homologues facilitating growth hormone release
ZA943612B (en) Inhibition of hair growth
EP0741578A4 (de) Menschliches wachstumshormon
ZA943611B (en) Inhibition of hair growth
IL134596A0 (en) Growth hormone secretagogues
EP0551923A3 (en) Consensus sync" data-sampling systems and methods
EP0726901A4 (de) Benzokondensierte makrocyclen die die freisetzung von wachstumshormon fördern
IL108142A0 (en) Aminoureaformaldehyde fertilizer composition and its preparation
GB9323124D0 (en) Novel benzo-fused lactams inhibit the release of growth hormone
GB2266244B (en) Condom
ZA93582B (en) Substituted hexahyhdroazephinones and tetrahydrobenzazepinones
GB9201778D0 (en) Fixing member and inserter
GB2279696B (en) Locking of letterboxes
KR950000006Y1 (en) Fastenings of sport-shoes
GB9314512D0 (en) Composition and use
PL299500A1 (en) Polymeric lewis' x-saccharides and method of obtaining the sames

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960520

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 960520;SI PAYMENT 960520

A4 Supplementary search report drawn up and despatched

Effective date: 19990604

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19991012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010903